Key result
Puerarin upregulated CAV3 protein expression in H9c2 cardiomyocytes and inhibited NF-κB and p38MAPK pathways, reducing high-glucose and high-lipid-induced inflammation and apoptosis.
Why the study?
Puerarin reduces HGHL-induced cardiomyocyte inflammation, apoptosis, and hypertrophy, but the underlying mechanisms were not determined.
Does puerarin reduce high-glucose and high-lipid-induced inflammatory injury in H9c2 cardiomyocytes?
Does puerarin reduce high-glucose and high-lipid-induced inflammatory injury in H9c2 cardiomyocytes?
Puerarin protects H9c2 cardiomyocytes against high-glucose and high-lipid-induced injury by upregulating CAV3 and inhibiting NF-κB and p38MAPK pathways, suggesting a potential mechanism for treating diabetic cardiomyopathy.
Hypothesis-generating for puerarin in metabolic cardiomyopathy; does not support clinical use without in vivo validation.
Background: Inflammation plays a crucial role in the development of diabetic cardiomyopathy (DCM), including inflammation caused by high-glucose and high-lipid (HGHL). Targeting inflammation may provide a useful strategy for preventing and treating DCM. Puerarin has been shown to reduce the inflammation, apoptosis and hypertrophy of cardiomyocytes induced by HGHL, in which this study aims to investigate the underlying mechanisms. Methods: H9c2 cardiomyocytes cultured with HGHL were used to establish a cell model of DCM. Puerarin was then placed to these cells for 24 hours. The effects of HGHL and puerarin on cell viability and apoptosis were investigated by the Cell Proliferation, Toxicity Assay Kit (CCK-8) and flow cytometry. Morphological changes of cardiomyocytes was observed by HE staining. CAV3 proteins in H9c2 cardiomyocytes were altered by transient transfection of CAV3 siRNA. IL-6 was detected by ELISA. The Western blot was performed to determine the CAV3, Bcl-2, Bax, pro-Caspase-3, cleaved-Caspase-3, NF-κB (p65) and p38MAPK proteins. Results: Puerarin treatment reversed the cells viability, hypertrophy in morphology, inflammation (showed by p-p38 and p-p65 and IL-6) and apoptosis-related damage (showed by cleaved-Caspase-3/pro-Caspase-3/Bax, Bcl-2 and flow cytometry) of the H9c2 cardiomyocyte caused by HGHL. Puerarin treatment also restored the decrease of CAV3 proteins of the H9c2 cardiomyocyte caused by HGHL. When silenced the expression of CAV3 proteins with SiRNA, puerarin failed to decreased p-p38 and p-p65 and IL-6, and could not reversed cell viability and morphological damage. In contrast to the simple CAV3 silenced group, the CAV3 silenced with NF-κB pathway or p38MAPK pathway inhibitors, significantly downregulated the p-p38, p-p65 and IL-6. Conclusion: Puerarin upregulated CAV3 protein expression in H9c2 cardiomyocytes and inhibited the NF-κB and p38MAPK pathways, thereby reducing HGHL-induced inflammation and may related to the apoptosis and hypertrophy of cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2023) studied Diabetic cardiomyopathy (cell model). Puerarin vs. High-glucose and high-lipid alone / CAV3 siRNA was evaluated on Cell viability, hypertrophy, inflammation, and apoptosis. Puerarin upregulated CAV3 protein expression in H9c2 cardiomyocytes and inhibited NF-κB and p38MAPK pathways, reducing high-glucose and high-lipid-induced inflammation and apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: